Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 2/3 2Phase NA 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Endocrine 3Thoracic 1CNS 1

Conditions

Brain Neoplasms 484Glioma 227Glioblastoma 223Neoplasms 62Neuroblastoma 56Central Nervous System Neoplasms 56Breast Neoplasms 54Meningioma 48Astrocytoma 42Neuroma, Acoustic 38Spinal Cord Neoplasms 35Neurofibromatosis 1 32Sarcoma 29Lung Neoplasms 29Oligodendroglioma 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma 27Neoplasm Metastasis 26Head and Neck Neoplasms 25Melanoma 22Lymphoma, Non-Hodgkin 22Leukemia 22Meningeal Carcinomatosis 21Medulloblastoma 21Hodgkin Disease 21Burkitt Lymphoma 20Testicular Neoplasms 19Lymphoma, Follicular 19Multiple Myeloma 18Gliosarcoma 18

Interventions

Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Thyroid Carcinoma, Anaplastic × CNS × Clear all
NCT00068497 2013-01-14

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase NA Completed
40 enrolled
CNSEndocrineHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Parathyroid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡